Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fate Therapeutics Inc FATE

Healthcare Biotechnology
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological... see more

Recent & Breaking News (NDAQ:FATE)

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire November 8, 2023

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

GlobeNewswire October 25, 2023

Fate Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire August 31, 2023

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

GlobeNewswire August 8, 2023

Grabar Law Office Investigates Claims on Behalf of Shareholders of Fate Therapeutics, Inc. (FATE)

Newsfile August 3, 2023

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

GlobeNewswire July 28, 2023

FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE

Business Wire June 30, 2023

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire June 21, 2023

Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire June 8, 2023

FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE

Business Wire June 5, 2023

Fate Therapeutics to Present at Upcoming June Investor Conferences

GlobeNewswire May 31, 2023

Grabar Law Office Investigates Claims on Behalf of Shareholders of Fate Therapeutics, Inc. (FATE)

Newsfile May 8, 2023

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

GlobeNewswire May 3, 2023

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

GlobeNewswire April 24, 2023

FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

Business Wire March 22, 2023

Fate Class Action: Levi & Korsinsky Reminds Fate Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 22, 2023 - FATE

Newsfile March 22, 2023

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 22, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)

PR Newswire March 22, 2023

FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire March 21, 2023

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

Business Wire March 21, 2023